Esperion Therapeutics, Inc. (ESPR)
USD 1.0
(-2.05%)
USD 1.0
(-2.05%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 501.54 Million USD | 92.48% |
| 2022 | 260.56 Million USD | 0.68% |
| 2021 | 258.8 Million USD | 41.56% |
| 2020 | 182.82 Million USD | 16385.21% |
| 2019 | 1.1 Million USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | -100.0% |
| 2016 | 1.02 Million USD | -61.98% |
| 2015 | 2.68 Million USD | -37.47% |
| 2014 | 4.29 Million USD | 0.0% |
| 2013 | - USD | -100.0% |
| 2012 | 7.52 Million USD | 9.16% |
| 2011 | 6.89 Million USD | 0.0% |
| 2002 | 7.73 Million USD | 41.03% |
| 2001 | 5.48 Million USD | 81.1% |
| 2000 | 3.02 Million USD | 32.54% |
| 1999 | 2.28 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 517.22 Million USD | -47.34% |
| 2024 Q1 | 498.43 Million USD | -0.62% |
| 2023 Q3 | 263.21 Million USD | 0.29% |
| 2023 FY | 501.54 Million USD | 92.48% |
| 2023 Q1 | 261.09 Million USD | 0.2% |
| 2023 Q4 | 501.54 Million USD | 90.55% |
| 2023 Q2 | 262.44 Million USD | 0.51% |
| 2022 Q1 | 258.94 Million USD | 0.05% |
| 2022 FY | 260.56 Million USD | 0.68% |
| 2022 Q2 | 259.21 Million USD | 0.11% |
| 2022 Q3 | 259.53 Million USD | 0.12% |
| 2022 Q4 | 260.56 Million USD | 0.4% |
| 2021 Q3 | 273.82 Million USD | -0.07% |
| 2021 Q4 | 258.8 Million USD | -5.48% |
| 2021 Q2 | 274.01 Million USD | -0.07% |
| 2021 FY | 258.8 Million USD | 41.56% |
| 2021 Q1 | 274.21 Million USD | 49.99% |
| 2020 Q2 | 3.96 Million USD | 6.67% |
| 2020 Q1 | 3.71 Million USD | 235.35% |
| 2020 Q3 | 4.1 Million USD | 3.48% |
| 2020 Q4 | 182.82 Million USD | 4353.62% |
| 2020 FY | 182.82 Million USD | 16385.21% |
| 2019 FY | 1.1 Million USD | 0.0% |
| 2019 Q2 | 759 Thousand USD | -4.17% |
| 2019 Q4 | 1.1 Million USD | 35.24% |
| 2019 Q3 | 820 Thousand USD | 8.04% |
| 2019 Q1 | 792 Thousand USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 Q2 | 140 Thousand USD | -76.07% |
| 2017 FY | - USD | -100.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | -100.0% |
| 2017 Q1 | 585 Thousand USD | -42.76% |
| 2016 FY | 1.02 Million USD | -61.98% |
| 2016 Q1 | 2.28 Million USD | -15.07% |
| 2016 Q2 | 1.87 Million USD | -18.05% |
| 2016 Q3 | 1.45 Million USD | -22.45% |
| 2016 Q4 | 1.02 Million USD | -29.57% |
| 2015 Q4 | 2.68 Million USD | -12.84% |
| 2015 FY | 2.68 Million USD | -37.47% |
| 2015 Q1 | 3.85 Million USD | -10.33% |
| 2015 Q2 | 3.47 Million USD | -9.91% |
| 2015 Q3 | 3.08 Million USD | -11.2% |
| 2014 Q4 | 4.29 Million USD | -8.06% |
| 2014 Q2 | 4.92 Million USD | 0.0% |
| 2014 FY | 4.29 Million USD | 0.0% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q3 | 4.67 Million USD | -5.0% |
| 2013 Q1 | - USD | -100.0% |
| 2013 FY | - USD | -100.0% |
| 2013 Q4 | - USD | 0.0% |
| 2013 Q3 | - USD | 0.0% |
| 2013 Q2 | - USD | 0.0% |
| 2012 FY | 7.52 Million USD | 9.16% |
| 2012 Q4 | 7.52 Million USD | 0.0% |
| 2011 FY | 6.89 Million USD | 0.0% |
| 2003 Q1 | 7.72 Million USD | -0.13% |
| 2003 Q2 | 7.94 Million USD | 2.94% |
| 2003 Q3 | 8.07 Million USD | 1.59% |
| 2002 Q3 | 7.22 Million USD | -2.9% |
| 2002 Q2 | 7.43 Million USD | 7.46% |
| 2002 Q4 | 7.73 Million USD | 7.06% |
| 2002 FY | 7.73 Million USD | 41.03% |
| 2002 Q1 | 6.92 Million USD | 26.25% |
| 2001 Q1 | 3.3 Million USD | 9.25% |
| 2001 Q2 | 5.12 Million USD | 55.1% |
| 2001 Q3 | 5.38 Million USD | 5.01% |
| 2001 Q4 | 5.48 Million USD | 1.78% |
| 2001 FY | 5.48 Million USD | 81.1% |
| 2000 Q3 | 2.48 Million USD | 25.72% |
| 2000 Q1 | 2.12 Million USD | 0.0% |
| 2000 FY | 3.02 Million USD | 32.54% |
| 2000 Q2 | 1.97 Million USD | -6.99% |
| 2000 Q4 | 3.02 Million USD | 21.91% |
| 1999 FY | 2.28 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 489.96 Million USD | -2.364% |
| Embecta Corp. | 1.62 Billion USD | 69.143% |
| ANI Pharmaceuticals, Inc. | 309.66 Million USD | -61.962% |
| Dynavax Technologies Corporation | 252.41 Million USD | -98.697% |
| Pacira BioSciences, Inc. | 513.79 Million USD | 2.384% |
| PainReform Ltd. | 30 Thousand USD | -1671720.0% |
| Aquestive Therapeutics, Inc. | 91.07 Million USD | -450.69% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -92945.164% |
| SCYNEXIS, Inc. | 12.15 Million USD | -4024.895% |
| China SXT Pharmaceuticals, Inc. | 117.12 Thousand USD | -428099.677% |
| Cosmos Health Inc. | 3.03 Million USD | -16423.547% |
| Journey Medical Corporation | 14.62 Million USD | -3330.078% |
| Sunshine Biopharma, Inc. | 539.03 Thousand USD | -92945.164% |
| Safety Shot Inc | 304.9 Thousand USD | -164391.468% |
| Alpha Teknova, Inc. | 13.25 Million USD | -3684.967% |
| Intra-Cellular Therapies, Inc. | 13.32 Million USD | -3663.665% |
| Bright Green Corporation | 201.78 Thousand USD | -248457.113% |
| Procaps Group, S.A. | 28.41 Million USD | -1665.385% |
| Theratechnologies Inc. | 51.26 Million USD | -878.416% |
| Harrow Health, Inc. | 183.17 Million USD | -173.811% |
| Sonoma Pharmaceuticals, Inc. | 87 Thousand USD | -576389.655% |
| Biofrontera Inc. | 804 Thousand USD | -62281.343% |
| DURECT Corporation | 2.7 Million USD | -18462.028% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -1410.863% |
| Cronos Group Inc. | 1.55 Million USD | -32071.007% |
| OptiNose, Inc. | 611 Thousand USD | -81986.088% |
| Ironwood Pharmaceuticals, Inc. | 498.3 Million USD | -0.65% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -1366.938% |
| RedHill Biopharma Ltd. | 455 Thousand USD | -110129.89% |
| Organogenesis Holdings Inc. | 60.74 Million USD | -725.658% |
| Guardion Health Sciences, Inc. | - USD | -Infinity% |
| Cumberland Pharmaceuticals Inc. | 12.78 Million USD | -3823.188% |
| Radius Health, Inc. | 339.66 Million USD | -47.659% |
| Universe Pharmaceuticals INC | - USD | -Infinity% |
| ProPhase Labs, Inc. | 10.25 Million USD | -4789.316% |
| Phibro Animal Health Corporation | 458.28 Million USD | -9.439% |
| Procaps Group S.A. | 28.41 Million USD | -1665.385% |
| Alvotech | 1.02 Billion USD | 51.2% |
| TherapeuticsMD, Inc. | 6.53 Million USD | -7578.291% |
| Viatris Inc. | 16.18 Billion USD | 96.902% |
| Rockwell Medical, Inc. | 8.29 Million USD | -5947.824% |
| Aytu BioPharma, Inc. | 10.87 Million USD | -4511.069% |
| SIGA Technologies, Inc. | 335.99 Thousand USD | -149173.641% |
| Tilray Brands, Inc. | 287.93 Million USD | -74.187% |
| Lifecore Biomedical, Inc. | 120.51 Million USD | -316.186% |
| Shineco, Inc. | 10.01 Million USD | -4906.782% |
| PetIQ, Inc. | 437.82 Million USD | -14.555% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Incannex Healthcare Limited | 210 Thousand USD | -238731.429% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -94.172% |
| Alimera Sciences, Inc. | 64.48 Million USD | -677.723% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Assertio Holdings, Inc. | 38.51 Million USD | -1202.243% |
| Shuttle Pharmaceuticals Holdings, Inc. | 135.08 Thousand USD | -371170.792% |
| Petros Pharmaceuticals, Inc. | 6.85 Million USD | -7213.977% |
| Clever Leaves Holdings Inc. | 720 Thousand USD | -69559.167% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2230579.594% |
| Avadel Pharmaceuticals plc | 32.75 Million USD | -1430.971% |
| Hempacco Co., Inc. | 5.93 Million USD | -8356.347% |
| Talphera, Inc. | - USD | -Infinity% |
| Alvotech | 1.02 Billion USD | 51.2% |
| Eagle Pharmaceuticals, Inc. | 56.21 Million USD | -792.177% |
| Lantheus Holdings, Inc. | 616.12 Million USD | 18.596% |
| Currenc Group, Inc. | 2.5 Million USD | -19906.031% |
| Kamada Ltd. | 7.43 Million USD | -6643.022% |
| Indivior PLC | 235.66 Million USD | -112.82% |
| Evoke Pharma, Inc. | 5 Million USD | -9930.92% |
| Flora Growth Corp. | 942 Thousand USD | -53142.675% |
| Cyclo Therapeutics, Inc. | 22.48 Thousand USD | -2230579.594% |
| Evolus, Inc. | 120.35 Million USD | -316.708% |
| HUTCHMED (China) Limited | 48.18 Million USD | -940.789% |
| Amphastar Pharmaceuticals, Inc. | 589.19 Million USD | 14.877% |
| Akanda Corp. | 2.49 Million USD | -19984.696% |